Mr. de Sousa is a medical doctor by training, having earned his degree at School of Medicine, University of Lisbon and holds an Executive MBA from the Stern School of Business, New York University. He comes to Immunicum with more than 25 years of senior level experience in the global pharmaceutical and biotech industry, including business development, mergers & acquisitions, global marketing and clinical development. Prior to joining Immunicum, he held senior positions at Nycomed/Takeda, Pfizer, Novartis, BBB Therapeutics, Newron Pharmaceuticals and, most recently, as Chief Business Officer at Zealand Pharma in Denmark.
Carlos de Sousa
Chief Executive Officer
M.D., Executive MBA
Chief Medical Officer
M.D., Ph.D. Digestive Oncologist
Peter Suenaert is a gastroenterologist – oncologist by training (University of Leuven, Leuven, Belgium, and McGill University, Montreal, Canada) and holds a Ph.D. in gut barrier function in relation to inflammatory bowel diseases from the University of Leuven, Belgium.
Prior to joining Immunicum, Dr. Suenaert served as Global Clinical Program Lead for oncology and Senior Director of Clinical Sciences at Glenmark Pharmaceuticals R&D in London, where he was heading up the clinical oncology unit (immune oncology assets) from start-up stage to being fully operational phase I/II protocol development.
Prior to that role, he was Director and Head of Clinical Development and Human Translational Research, a position with global reach, and member of the global management team Life Science at Danone Research in Palaiseau (Paris), France. Previously, Dr. Suenaert was Clinical Research and Development Leader in global early cancer immunotherapeutics development at GlaxoSmithKline Vaccines in Rixensart, Belgium and Clinical Research Senior Medical Scientist, Global Development, Haematology / Oncology at AMGEN in the U.K.
Chief Financial Officer
Bachelor of Science (BSc) in Business Administration And Economics
Lise-Lotte Hallbäck holds a Bachelor of Science (BSc) in Business Administration And Economics, Växjö University/Linnaeus University.
She has previously worked as Chartered Public Accountant, Management Consultant and Financial Manager. Lise-Lotte has a long and wide experience within accounting and financial management and has mainly worked with international companies.
Chief Scientific Officer
M.D., Ph.D. Adjunct Professor in Clinical Immunology, Uppsala University, Sweden
Adjunct Professor Karlsson-Parra has over 20 years of experience working in the field of transplantation immunology and is former chairman of the Swedish Expert Group for Clinical Immunology. He was awarded the Athena Prize, the Swedish healthcare’s most prestigious award for clinical research, in 2014.
He was formerly Associate Professor and chief physician at the Department of Clinical Immunology at Sahlgrenska University Hospital, Gothenburg.
Head of CMC
Ph.D. in Virology
Sharon Longhurst joins Immunicum from her previous position as Senior CMC Manager at Akari Therapeutics, where she was responsible for all aspects of CMC for an innovative biologic product, Coversin, including clinical supply and distribution. Prior to that, Sharon spent 5 years as Principal Consultant of CMC at Parexel Consulting. From 2005–2011, she was a Pharmaceutical Assessor at MHRA in London in the biologics/biotechnology unit and provided national and EU scientific advice for Advance Therapy Medicinal Products (ATMPs) for cell and gene therapy. Sharon graduated from the University of Warwick, Coventry, UK with a PhD in Virology.
Head of Regulatory and QA
Margareth Jorvid has over 30 years’ experience in Regulatory Affairs for pharmaceuticals and has worked at the Medical Products Agency (MPA), as well as in large and small pharmaceutical companies such as Roussel Nordiska, Hoechst Marion Roussel (Stockholm and Paris, France) and Neopharma (SME company that developed Duodopa for the treatment of severe Parkinson’s disease). Since 2006, consultant in regulatory affairs and quality assurance for pharmaceuticals and medical devices, as CEO of Methra Uppsala AB, LSM group. Margareth has a pharmacy degree from Uppsala University, MBA from the Stockholm School of Economics and a MSc in Medical Technology Regulatory Affairs (medical devices) from Cranfield University, UK. She is a Fellow and Honorary Life Member of TOPRA (The Organisation for Professionals in Regulatory Affairs), after years of work with education and training in regulatory affairs, board member and TOPRA President 2005-2006.
Senior Director Business Development
Sijme Zeilemaker joins Immunicum having most recently served as Director Business Development at InteRNA Technologies where he supported the preclinical oncology company in connecting with pharmaceutical and biotechnology companies, licensing technologies and exploring grant opportunities. Sijme also served as Head of Business for 2-BBB Medicines and Business Development Manager for to-BBB technologies where he provided partnering support and attracted over €7.5 million in non-dilutive funding. Sijme obtained a Masters degree in Biomedical Sciences from Leiden University, The Netherlands.